Yield10 insider Jack Schuler bought $1.5M of YTEN on Aug. 26. The stock soared 53% on Sept 10.

0
202

Jack Schuler is the former President/COO of Abbott Laboratories and a biotech entrepreneur with a penchant for investing in medical stocks both large and small. On Aug. 31, Schuler filed a 13D/A disclosing the purchase of 365,291 shares of the bioscience company Yield10 (YTEN) @ 4.25. At that price, YTEN had a market cap of just $13.6 million. Insider Jack Schuler bought the shares in a private placement and public offering that netted the company about $4.8M. Schuler controlled 1,634,063 shares — or about 51% of the company — after the purchases.

The transactions were very well-timed.

Because on Thursday, H.C. Wainwright analyst Amit Dayal initiated coverage of Yield10 Bioscience with a Buy rating and $25 price target. YTEN shares surged as high as $8.45 — up 94% — before closing at $6.67.

Yield10 Bioscience (YTEN) 5 minute chart showing gap after HC Wainwright initiated coverage with a buy rating and a $25 target. Chart source: Interactive Brokers.

Yield10 Bioscience, Inc., formerly Metabolix, Inc. is focused on developing crop innovations for sustainable global food security. The company’s technologies improve crop yield for food and feed crops. YTEN is developing ways to improve fundamental elements of plant photosynthetic efficiency by directing more carbon to seed production. The company is advancing several yield traits it has developed in crops, such as Camelina, canola, soybean and corn. The plan is to partner with major agricultural companies to drive new traits into development for canola, soybean, corn and other commercial crops.

H.C. Wainwright initiated coverage of Yield10 with a $25 target — 350% above the stock’s close on Sept. 11.

According to Dayal, the market is not assigning any meaningful value to the expected increase in Camelina production acreage from 50 acres in 2020 to 50,000 acres in 2021. Also, investors are undervaluing the company’s fifteen seed and yield traits at various stages of development and approvals on three non-regulated traits. The analyst believes Yield10 is on the cusp of generating “meaningful” revenue beginning in 2021 from product sales and potential licensing deals. On Sept. 9, the company announced it would participate at the H.C. Wainwright 22nd Annual global Investment Conference on September 14-16.

While YTEN stock is up nearly 60% in the two weeks since insider Jack Schuler significantly increased his stake in the company, the investor is no Johnny-come-lately to the company. He first bought shares of Yield10, then called Metabolix, in Sept. of 2011 when the company went by the name Metabolix.

YTEN insider Jack Schuler is a significant owner of other publicly traded companies. The largest is Quidel Corp (QDEL), a $691M position. Schuler was a director of the diagnostic testing company for 14 years, retiring in June.

Jack W. Shuler’s top holdings.

StockShares HeldMarket ValueSourceSource Date
Quidel Corp. (QDEL)4,292,374691,072,21413D5/20/19
Accelerate Diagnostics Corp (AXDX)17,079,791178,313,01813D3/27/18
Aspira Womens Health Inc (VRML)25,751,78773,907,62813D7/1/20
Soleno Therapeutics Inc (SLNO)12,644,97230,095,03313D3/21/19
Yield10 Bioscience Inc (YTEN)793,6355,555,44513D8/26/20
Biolase Inc (BIOL)6,507,4861,952,24613D6/10/20
Neos Therapeutics Inc (NEOS)2,338,6711,590,29613G12/31/17
Jack W Schuler top holdings, based on SEC Filings. Source: WhaleWisdom.com

Disclaimer:

This investment blog (the “Blog”) is created and authored by Mark W. Gaffney (the “Content Creator”). The Blog is provided for informational and entertainment purposes only (collectively, the “Blog Service”). The information in the Blog constitutes the Content Creator’s own opinions. None of the information contained in the Blog constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You understand that the Content Creator is not advising, and will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent any of the information contained in the Blog may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

From time to time, the Content Creator or its affiliates may hold positions or other interests in securities mentioned in the Blog. The Content Creator or affiliates may trade for their own account(s) based on the information presented, and may also take positions inconsistent with the views expressed in its messages on the Blog.

The Content Creator may hold licenses with FINRA, the SEC or states securities authorities. These licenses may or may not be disclosed by the Content Creator in the Blog.

Investing in the investments discussed in the Blog may be risky and speculative. The companies may have limited operating histories, little available public information. The stocks discussed may be volatile and illiquid. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital not required for other purposes, such as retirement savings, student loans, mortgages or education.

Full Disclaimer.